Where does Novira Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Novira Therapeutics, Inc. ranks #7,600 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Novira Therapeutics, Inc. hold?

Novira Therapeutics, Inc. holds 43 US utility patents granted between 2015 and 2021, spanning 8 technology areas.

What is Novira Therapeutics, Inc.'s Innovation Score?

Novira Therapeutics, Inc. has an Innovation Score of 33.4 out of 100 (44th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Novira Therapeutics, Inc. focus on?

Novira Therapeutics, Inc.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 41 patents, ranking #545 of 7,163 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Novira Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Novira Therapeutics, Inc.'s recent grant velocity is -74% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Novira Therapeutics, Inc.'s patents?

Novira Therapeutics, Inc.'s patents average 17.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Novira Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Novira Therapeutics, Inc.

USPTO PatentsView assignee record - 43 granted patents across 8 technology areas, recorded in grant years 2015–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Novira ranks #7,600 of 49,997 tracked US assignees by granted-patent volume, with 43 patents across 8 technology areas.

#7,600
of 49,997 US assignees by volume: 44th percentile
by Innovation Score (33.4/100): 17.2
avg claims per patent: -74%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R7600 · US Corporation #7,600 · 43 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 43 grants
UPPER-Q #7,600/49,997
PHOTO-FINISH Neurometrix
CPC-NARROW A61K · 8 areas
INNOV-THIN 33.4/100
CLAIMS-RICH 17.2 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -74% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Neurometrix, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Novira’s 33.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.1 pts (39%) Velocity 0.0 pts (0%) Breadth 10.0 pts (30%) Claim depth 10.3 pts (31%)

Qualcomm Incorporated · highest

85
Curiteva · near

33
Novira Therapeutics · this assignee

33
Q3 Medical Devices · near

33
Evga · near

33
Kirintec · near

33
3D Lighting… · lowest

7

What this shows Novira's Innovation Score is 33.4/100 (44th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Novira?

Each dot is one of Novira’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Novira’s own 17.2 claims/patent is at or below the 19.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Novira vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Novira's grants concentrate

Novira Therapeutics, Inc. is a focused PatentsView assignee: 8 CPC subclasses with 95.3% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2019 (8 grants) versus a trough of 3 in 2021. By volume, Novira sits between Neurometrix, Inc. and Ooma, Inc..

Neurometrix

43
Nok Nok Labs

43
Nokia Siemens Net…

43
Norgren

43
Opko Diagnostics

43
Optis Circuit Tec…

43
Oupiin (Kunshan)

43
Ooma

43
Novira Therapeuti… ◀

43

What this shows Novira holds 43 patents at rank #7,600, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Novira

By rank, the assignees closest to #7,600 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Novira's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Novira, neither rank-band nor same-CPC leaders (those blocks stay above). In A61K (Preparations FOR Medical), Novira ranks #545 of 7,163 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (33 here).

Q3 Medical Devices Limited 33 Curiteva, Inc. 33 Evga Corporation 33 Kirintec Limited 33

Novira's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 44th percentile higher than 44% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Novira Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	7	16.3%
2016	5	11.6%
2017	7	16.3%
2018	7	16.3%
2019	8	18.6%
2020	6	14.0%
2021	3	7.0%

Which technologies does Novira Therapeutics, Inc. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 41

C07D - Heterocyclic Compounds 39

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 34

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 12

C07C - Acyclic OR Carbocyclic Compounds 8

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Novira Therapeutics, Inc.'s patent record in context - here's where to go next.

Novira Therapeutics, Inc.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 95.3% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #7,600 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Novira Therapeutics, Inc. against Neurometrix, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 33.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.